News
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics reports positive study results for RLF-OD032, showing superior absorption in fasted state compared to KUVAN®, enabling flexible dosing. New patents filed for innovative PKU treatment -
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets -
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics reports promising preliminary results of RLF-TD011 clinical trial for epidermolysis bullosa, showing reduced Staphylococcus aureus and improved microbiome diversity -
-
